36914-69-9

Basic information

• Product Name: 1-PHENYL-2-PYRAZIN-2-YL ETHANOL
• Synonyms: 1-PHENYL-2-PYRAZIN-2-YL ETHANOL;alpha-Phenylpyrazineethanol;1-Phenyl-2-(2-pyrazinyl)ethanol
• CAS NO: 36914-69-9
• Molecular Formula: C₁₂H₁₂N₂O
• Molecular Weight: 200.24
• Mol File: 36914-69-9.mol
• Article Data: 5

Chemical Properties

• Melting Point: 88-90°C
• Boiling Point: 328.3 °C at 760 mmHg
• Flash Point: 152.4 °C
• Appearance: /
• Density: 1.194 g/cm³
• Vapor Pressure: 7.7E-05mmHg at 25°C
• Refractive Index: 1.608
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-PHENYL-2-PYRAZIN-2-YL ETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PHENYL-2-PYRAZIN-2-YL ETHANOL(36914-69-9)
• EPA Substance Registry System: 1-PHENYL-2-PYRAZIN-2-YL ETHANOL(36914-69-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 36914-69-9(Hazardous Substances Data)

Usage

General Description

1-PHENYL-2-PYRAZIN-2-YL ETHANOL is a chemical compound with the molecular formula C14H14N2O. It is a white crystalline solid with a molecular weight of 226.28 g/mol. 1-PHENYL-2-PYRAZIN-2-YL ETHANOL is a pyrazine derivative with a phenyl and an ethanol group attached. It is commonly used in pharmaceutical research and development as a building block for the synthesis of various bioactive compounds. Additionally, 1-PHENYL-2-PYRAZIN-2-YL ETHANOL has been studied for its potential anti-inflammatory and analgesic properties, making it a promising candidate for drug development in the field of pain management and inflammation treatment. Overall, this compound holds potential for various applications in the pharmaceutical industry due to its unique chemical structure and potential therapeutic effects.

InChI:InChI=1/C12H12N2O/c15-12(10-4-2-1-3-5-10)8-11-9-13-6-7-14-11/h1-7,9,12,15H,8H2

Upstream product

• 109-08-0 2-Methylpyrazine 
• 100-52-7 benzaldehyde 
• 1251919-99-9 potassium 2-(pyrazin-2-yl)acetate 

Downstream Products

• 109-08-0 2-Methylpyrazine 
• 100-52-7 benzaldehyde 
• 126474-08-6 3-Phenyl-3,4-dihydro-1H-pyrano[4,3-c]pyridine 
• 126474-07-5 7-Phenyl-7,8-dihydro-5H-pyrano[4,3-b]pyridine 
• 126474-23-5 3-Phenyl-8-trimethylsilanyl-3,4-dihydro-1H-pyrano[4,3-c]pyridine 
• 126474-22-4 7-Phenyl-4-trimethylsilanyl-7,8-dihydro-5H-pyrano[4,3-b]pyridine 
• 126474-13-3 2-[2-Phenyl-2-(3-trimethylsilanyl-prop-2-ynyloxy)-ethyl]-pyrazine 
• 36680-26-9 styryl-pyrazine 
• 1007107-23-4 C₁₂H₁₂N₂O 
• 1007107-16-5 C₂₅H₃₀N₂OSi 

Relevant articles and documents

Direct reversible decarboxylation from stable organic acids in dimethylformamide solution

Many classical and emerging methodologies in organic chemistry rely on carbon dioxide (CO2) extrusion to generate reactive intermediates for bond-forming events. Synthetic reactions that involve the microscopic reverse-the carboxylation of reactive intermediates-have conventionally been undertaken using very different conditions. We report that chemically stable C(sp3) carboxylates, such as arylacetic acids and malonate half-esters, undergo uncatalyzed reversible decarboxylation in dimethylformamide solution. Decarboxylation-carboxylation occurs with substrates resistant to protodecarboxylation by Br?nsted acids under otherwise identical conditions. Isotopically labeled carboxylic acids can be prepared in high chemical and isotopic yield by simply supplying an atmosphere of 13CO2 to carboxylate salts in polar aprotic solvents. An understanding of carboxylate reactivity in solution enables conditions for the trapping of aldehydes, ketones, and a,b-unsaturated esters.

Novel heterocyclic urea derivatives and their use as dopamine D3 receptor ligands

The invention relates to heterocyclic substituted urea derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D3 receptors.

Studies on the Thermolysis of 2-(2-Hydroxy-2-arylethyl)pyrazines. An Example of a Retro-Ene-Type Reaction

Several substituted 2-(2-hydroxy-2-arylethyl)pyrazines (1-10) have been prepared and their thermolysis in diglyme and DMF studied.Each of these substrates decomposes to give the parent methylpyrazine and the corresponding aryl aldehyde.Kinetic, isotope effect, and solvent effect studies suggest a mechanism involving a nonpolar concerted six-membered-ring transition state.The degree of proton transfer in the transition state is discussed in detail.Methyl substituents on the pyrazine ring were found to strongly affect the reaction rate.This phenomenon is analyzed interms of the steric and electronic effects induced by the methyl substituents.